Variation in management of lymph node positive prostate cancer after radical prostatectomy within a statewide quality improvement consortium

Authors: Triner, Daniel, Daignault-Newton, Stephanie, Singhal, Udit, Sessine, Michael, Dess, Robert T., Caram, Megan E V, Borza, Tudor, Ginsburg, Kevin B., Lane, Brian R., Morgan, Todd M.

Source: In Urologic Oncology: Seminars and Original Investigations July 2024 42(7):220-220

Detection of Germline Variants in Patients With Localized and Metastatic Prostate Cancer Through Guideline-Based Testing.

Authors: Abusamra, Sophia M., Solorzano, Marissa A., Quarles, Jake, Luke, Mallory, Patel, Milan, Vince Jr, Randy, Jiang, Ralph, Volin, Joshua, Jacobs, Michelle F., Kaffenberger, Samuel D., Salami, Simpa S., Palmbos, Phillip, Caram, Megan E. V., Hollenbeck, Brent K., Palapattu, Ganesh S., Merajver, Sofia D., Stoffel, Elena M., Hafron, Jason, Morgan, Todd M., Reichert, Zachery R.

Source: Urology Practice; Jan2025, Vol. 12 Issue 1, p63-72, 10p

The 340B Drug Pricing Program and Management of Advanced Prostate Cancer.

Authors: Faraj, Kassem S., Kaufman, Samuel R., Oerline, Mary, Dall, Christopher, Srivastava, Arnav, Caram, Megan E. V., Shahinian, Vahakn B., Hollenbeck, Brent K.

Source: Cancer Medicine; Jan2025, Vol. 14 Issue 1, p1-7, 7p

Subject Terms: ANDROGEN receptors, POOR people, PROSTATE cancer patients, ANTIANDROGENS, HEALTH equity

The 340B Program and High-Risk Prescribing of Oral Targeted Therapies for Advanced Prostate Cancer.

Authors: Faraj, Kassem S., Oerline, Mary, Kaufman, Samuel R., Dall, Christopher, Srivastava, Arnav, Caram, Megan E. V., Shahinian, Vahakn B., Hollenbeck, Brent K.

Source: Urology Practice; Nov2024, Vol. 11 Issue 6, p930-938, 8p

Adverse events in men with advanced prostate cancer treated with androgen biosynthesis inhibitors and androgen receptor inhibitors.

Authors: Faraj, Kassem S, Oerline, Mary, Kaufman, Samuel R, Dall, Christopher, Srivastava, Arnav, Caram, Megan E V, Shahinian, Vahakn B, Hollenbeck, Brent K

Source: JNCI: Journal of the National Cancer Institute; Nov2024, Vol. 116 Issue 11, p1817-1824, 8p

Subject Terms: ANDROGEN receptors, EMERGENCY room visits, PROSTATE cancer patients, ANTIANDROGENS, MEDICARE beneficiaries

Addressing financial toxicity in cancer treatment—An opportunity for the 340B drug pricing program.

Authors: Faraj, Kassem S.¹ (AUTHOR) farajk@med.umich.edu, Caram, Megan E. V.^2,3 (AUTHOR), Shahinian, Vahakn B.⁴ (AUTHOR), Hollenbeck, Brent K.¹ (AUTHOR)

Source: Cancer (0008543X). Sep2024, Vol. 130 Issue 18, p3077-3081. 5p.

Subject Terms: *HEALTH policy, *DRUG prices, *HOSPITAL utilization, *CANCER patients, *HOSPITAL care, *SAFETY-net health care providers

Survival by first‐line therapy and prognostic group among men with metastatic castration‐resistant prostate cancer.

Authors: Caram, Megan E. V.^1,2 (AUTHOR) mveresh@med.umich.edu, Kumbier, Kyle² (AUTHOR), Tsao, Phoebe A.^1,2 (AUTHOR), Burns, Jennifer² (AUTHOR), Sparks, Jordan B.² (AUTHOR), Stensland, Kristian D.³ (AUTHOR), Reichert, Zachery R.¹ (AUTHOR), Alumkal, Joshi J.¹ (AUTHOR), Hollenbeck, Brent K.⁴ (AUTHOR), Shahinian, Vahakn^1,3 (AUTHOR), Tsodikov, Alexander⁵ (AUTHOR), Skolarus, Ted A.^2,6 (AUTHOR)

Source: Cancer Medicine. Jun2024, Vol. 13 Issue 12, p1-12. 12p.

Subject Terms: *CASTRATION-resistant prostate cancer, *MEDICAL care, *GROUP psychotherapy, *PROSTATE-specific antigen, *PROGRESSION-free survival, *OVERALL survival

The 340B Program and oral specialty drugs for advanced prostate cancer.

Authors: Faraj, Kassem S., Kaufman, Samuel R., Oerline, Mary, Herrel, Lindsey A., Maganty, Avinash, Caram, Megan E. V., Shahinian, Vahakn B., Hollenbeck, Brent K.

Source: Cancer (0008543X); Jun2024, Vol. 130 Issue 12, p2160-2168, 9p

Subject Terms: ORAL medication, PROSTATE cancer, PATIENT compliance, PROSTATE cancer patients, HEALTH equity, MEDICARE

Urologist practice divestment from radiation vault ownership and treatment patterns for prostate cancer.

Authors: Faraj, Kassem S., Kaufman, Samuel R., Herrel, Lindsey A., Maganty, Avinash, Oerline, Mary K., Caram, Megan E. V., Shahinian, Vahakn B., Hollenbeck, Brent K.

Source: Cancer (0008543X); May2024, Vol. 130 Issue 9, p1609-1617, 9p

Subject Terms: PROSTATE cancer, DISINVESTMENT, HEALTH care reform, PROSTATE cancer patients, UROLOGISTS, INCENTIVE (Psychology)

National Trends in Management of Newly Diagnosed Prostate Cancer.

Authors: Maganty, Avinash, Kaufman, Samuel R., Oerline, Mary K., Lai, Lillian Y., Caram, Megan E. V., Shahinian, Vahakn B., Hollenbeck, Brent K.

Source: Clinical Genitourinary Cancer; Apr2024, Vol. 22 Issue 2, p10-17, 8p

Subject Terms: PROSTATE cancer treatment, CANCER-related mortality, DECISION making in clinical medicine, CANCER hormone therapy, LIFE expectancy

This result is not displayed to guests.
Login for full access.

Determinants of Bone-Modifying Agent Prescribing for Metastatic Castration-Resistant Prostate Cancer in a National Health Care Delivery System.

Authors: Nguyen, Charles B., Kobe, Christopher, Kumbier, Kyle E., Bauman, Jordan, Burns, Jennifer A., Tsao, Phoebe A., Sparks, Jordan B., Skolarus, Ted A., Caram, Megan E. V.

Source: JCO Oncology Practice; Jan2024, Vol. 20 Issue 1, p59-68, 11p

Subject Terms: DRUG therapy, DIPHOSPHONATES, CONFIDENCE intervals, LIFE expectancy, MEDICAL care, RETROSPECTIVE studies, MANN Whitney U Test, FISHER exact test, CASTRATION-resistant prostate cancer, NATIONAL health services, MATHEMATICAL variables, BONE metastasis, DESCRIPTIVE statistics, CHI-squared test, RESEARCH funding, MEDICAL prescriptions, LOGISTIC regression analysis, ODDS ratio, LONGITUDINAL method

Value-based payment models and management of newly diagnosed prostate cancer.

Authors: Maganty, Avinash, Kaufman, Samuel R., Oerline, Mary K., Faraj, Kassem S., Caram, Megan E. V., Shahinian, Vahakn B., Hollenbeck, Brent K.

Source: Cancer Medicine; Jan2024, Vol. 13 Issue 1, p1-11, 11p

Subject Terms: PROSTATE cancer, ACCOUNTABLE care organizations, PROSTATE cancer patients, PAYMENT systems, PAYMENT, FINANCIAL risk

The immediate effects of private equity acquisition of urology practices on the management of newly diagnosed prostate cancer.

Authors: Faraj, Kassem S., Kaufman, Samuel R., Herrel, Lindsey A., Maganty, Avinash, Oerline, Mary, Caram, Megan E. V., Shahinian, Vahakn B., Hollenbeck, Brent K.

Source: Cancer Medicine; Dec2023, Vol. 12 Issue 24, p22325-22332, 8p

Subject Terms: PROSTATE cancer, PRIVATE equity, PROSTATE cancer patients, MULTILEVEL models, UROLOGY, TIME perspective

Acquisition of Urology Practices by Private Equity Firms and Performance in the Merit-based Incentive Payment System.

Authors: Faraj, Kassem S., Kaufman, Samuel R., Herrel, Lindsey A., Maganty, Avinash, Oerline, Mary, Caram, Megan E. V., Shahinian, Vahakn B., Hollenbeck, Brent K.

Source: Urology Practice; Nov2023, Vol. 10 Issue 6, p596-603, 7p

Outcomes after definitive radiation therapy for localized prostate cancer in a national health care delivery system.

Authors: Herr, Daniel J., Elliott, David A., Duchesne, Gillian, Stensland, Kristian D., Caram, Megan E. V., Chapman, Christina, Burns, Jennifer A., Hollenbeck, Brent K., Sparks, Jordan B., Shin, Chris, Zaslavsky, Alexander, Tsodikov, Alexander, Skolarus, Ted A.

Source: Cancer (0008543X); Oct2023, Vol. 129 Issue 20, p3326-3333, 8p

Subject Terms: MEDICAL care, NATIONAL health services, PROSTATE cancer, RADIOTHERAPY, NATURAL language processing, ANDROGEN deprivation therapy

Company/Entity: UNITED States. Veterans Health Administration

In-office dispensing of oral targeted agents by urology practices in men with advanced prostate cancer.

Authors: Hill, Dawson, Kaufman, Samuel R, Oerline, Mary K, Faraj, Kassem, Caram, Megan E V, Shahinian, Vahakn B, Hollenbeck, Brent K, Maganty, Avinash

Source: JNCI Cancer Spectrum; Oct2023, Vol. 7 Issue 5, p1-7, 7p

Health care delivery system contributions to management of newly diagnosed prostate cancer.

Authors: Krampe, Noah, Kaufman, Samuel R., Oerline, Mary K., Hill, Dawson, Caram, Megan E. V., Shahinian, Vahakn B., Hollenbeck, Brent K., Maganty, Avinash

Source: Cancer Medicine; Aug2023, Vol. 12 Issue 16, p17346-17355, 10p

Subject Terms: MEDICAL care, PROSTATE cancer, PROSTATE cancer patients, MONETARY incentives, LOGISTIC regression analysis

Mental health care utilization among men with castration‐resistant prostate cancer receiving abiraterone or enzalutamide.

Authors: Tsao, Phoebe A., Burns, Jennifer, Kumbier, Kyle, Sparks, Jordan B., Entenman, Shami, Bloor, Lindsey E., Bohnert, Amy S. B., Skolarus, Ted A., Caram, Megan E. V.

Source: Cancer Medicine; Aug2023, Vol. 12 Issue 15, p16490-16501, 12p

Subject Terms: MENTAL health services, MEDICAL care use, CASTRATION-resistant prostate cancer, PROSTATE cancer patients, MENTAL illness

Company/Entity: UNITED States. Veterans Health Administration

PD10-06 DETECTION OF GERMLINE VARIANTS IN PATIENTS WITH LOCALIZED AND METASTATIC PROSTATE CANCER THROUGH GUIDELINE-BASED TESTING.

Authors: Solorzano, Marissa A., Abusamra, Sophia M., Quarles, Jake, Luke, Mallory, Patel, Milan, Vince Jr, Randy, Jiang, Ralph, Volin, Joshua, Jacobs, Michelle F., Kaffenberger, Samuel, Salami, Simpa S., Palmbos, Phillip, Caram, Megan E. V., Palapattu, Ganesh S., Hollenbeck, Brent K., Merajver, Sofia D., Stoffel, Elena M., Hafron, Jason, Morgan, Todd M., Reichert, Zachery R.

Source: Journal of Urology; 2025 Supplement 5s, Vol. 213, pe375-e375, 1p